See what COSENTYX
can do for your patients

The first AND only
fully human monoclonal antibody
to selectively target il-17A

approved for moderate to severe plaque psoriasis, active psoriatic arthritis, and ankylosing spondylitis

See what COSENTYX can do for your patients

The first AND only fully human monoclonal antibody to selectively target il-17A

approved for moderate to severe plaque psoriasis, active psoriatic arthritis, and ankylosing spondylitis
Reference: Cosentyx [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2018.
Reference: Cosentyx [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2018.